利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

836 条记录 (耗时 0.046 秒)

    Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
    52.
    发明授权
    Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor 失效
    人二酰基甘油酰基转移酶2（DGAT2）家族成员及其用途

    公开(公告)号：US07910346B2

    公开(公告)日：2011-03-22

    申请号：US12378703

    申请日：2009-02-17

    申请人： Ruth E. Gimeno ,  Rosana Kapeller-Libermann ,  Zhidan Wu ,  Brian K. Hubbard

    发明人： Ruth E. Gimeno ,  Rosana Kapeller-Libermann ,  Zhidan Wu ,  Brian K. Hubbard

    IPC分类号： C12N9/10 ,  C12N1/20 ,  C12P7/64 ,  C12P15/70 ,  C07H21/04

    CPC分类号： C12N9/1029 ,  A01K2217/05 ,  C07K16/40 ,  C12Q1/48 ,  C12Y203/0102 ,  G01N33/573 ,  G01N2333/91051 ,  G01N2800/044

    摘要： The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.

    摘要翻译： 本发明涉及用于诊断和治疗肥胖症及相关代谢紊乱的组合物和方法。 本发明提供编码二酰基甘油酰基转移酶家族成员的分离的核酸分子，称为DGAT2家族成员核酸分子。 本发明还提供了含有DGAT2家族成员核酸分子的重组表达载体，已引入表达载体的宿主细胞，以及导入或破坏了DGAT2家族成员基因的非人类转基因动物。 本发明还进一步提供分离的DGAT2家族成员蛋白，融合蛋白，抗原肽和抗DGAT2家族成员抗体。 还公开了所提供的DGAT2家族成员组合物用于与肥胖症有关的筛选，诊断和治疗方法的方法。

    METHODS AND COMPOSITIONS FOR UPREGULATION OF PEROXIREDOXIN ACTIVITY
    55.
    发明申请
    METHODS AND COMPOSITIONS FOR UPREGULATION OF PEROXIREDOXIN ACTIVITY 审中-公开
    过氧化物酶活性升高的方法和组合物

    公开(公告)号：US20100297673A1

    公开(公告)日：2010-11-25

    申请号：US12441924

    申请日：2007-09-20

    申请人： Ish Khanna ,  Ram Pillarisetti ,  Uday Saxena

    发明人： Ish Khanna ,  Ram Pillarisetti ,  Uday Saxena

    IPC分类号： G01N33/53

    CPC分类号： C12Q1/28 ,  G01N33/92 ,  G01N2500/10 ,  G01N2800/044

    摘要： A novel method of identifying compounds capable of upregulating Peroxiredoxin activity is disclosed. The method includes providing a sample of cells that express Peroxiredoxin, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of Peroxiredoxin activity within the cell sample after the contacting step. Peroxiredoxin inducers identified by the method and uses therefore to upregulate Peroxiredoxin activity in subjects and to reduce LDL and/or VLDL levels and to prevent or treat atherosclerosis and inflammatory disorders such as arthritis in subjects are also described. The invention also provides a method of treatment of inflammatory and cardiovascular diseases which comprises providing a patient in need of treatment with an effective amount of a composition that increases Peroxiredoxin protein or activity.

    摘要翻译： 公开了鉴定能够上调过氧化还原毒素活性的化合物的新方法。 该方法包括提供表达过氧化还原毒素的细胞样品，提供候选化合物的样品，接触细胞样品和化合物样品，以及在接触步骤之后测量细胞样品内过氧化还原毒素活性的定量指标。 本文还描述了通过该方法和用途鉴定的过氧化还原毒素诱导剂，以上调受试者中的过氧化还原毒素活性并降低LDL和/或VLDL水平并预防或治疗动脉粥样硬化和炎症性疾病如受试者中的关节炎。 本发明还提供了一种治疗炎性和心血管疾病的方法，其包括提供需要治疗的患者，所述治疗有效量的增加过氧化还原蛋白或活性的组合物。

    ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF
    57.
    发明申请
    ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF 审中-公开
    ADIPONECTIN表达诱导剂及其用途

    公开(公告)号：US20100273708A1

    公开(公告)日：2010-10-28

    申请号：US12762437

    申请日：2010-04-19

    申请人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Shoko Kitajima ,  Yusuke Ito

    发明人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Shoko Kitajima ,  Yusuke Ito

    IPC分类号： A61K38/17 ,  A61P3/00

    CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K48/00 ,  G01N33/6875 ,  G01N33/74 ,  G01N33/92 ,  G01N2500/10 ,  G01N2800/044

    摘要： The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.

    摘要翻译： 本发明提供了脂联素表达诱导剂和使用其的治疗剂用于肥胖症和肥胖相关疾病如心血管疾病或代谢疾病，以及搜索脂联素表达诱导剂的方法。 KLF9可以结合位点-188的32-bp片段，从脂联素表达起始位点到位置-157，证明增强脂连蛋白启动子活性。 因此，本发明使用KLF9作为脂联素表达诱导剂，并且表明KLF9补充疗法可用于预防和/或治疗肥胖症或肥胖相关疾病，包括诸如胰岛素抵抗和II型糖尿病等代谢疾病和心血管疾病 。

    Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
    58.
    发明授权
    Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis 失效
    低密度脂蛋白结合蛋白及其在诊断和治疗动脉粥样硬化中的应用

    公开(公告)号：US07807384B2

    公开(公告)日：2010-10-05

    申请号：US12137832

    申请日：2008-06-12

    申请人： Ann M. Lees ,  Robert S. Lees ,  Simon W. Law ,  Anibal A. Arjona

    发明人： Ann M. Lees ,  Robert S. Lees ,  Simon W. Law ,  Anibal A. Arjona

    IPC分类号： G01N33/53 ,  C07K1/00

    CPC分类号： A61K49/0004 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/705 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/044 ,  G01N2800/323

    摘要： Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.

    摘要翻译： 描述了编码能够结合天然和甲基化的LDL（低密度脂蛋白），所述分离的多肽（称为LBP（LDL结合蛋白））及其生物活性片段及其类似物的分离的多核苷酸的分离多核苷酸。 还描述了用于确定动物是否处于动脉粥样硬化风险的方法，用于评估用于治疗动脉粥样硬化的药剂的方法，治疗动脉粥样硬化的方法，以及用于治疗LBP的结构或代谢异常的细胞的方法。 还提供药物组合物和疫苗组合物。

    METHOD FOR PREDICTING RESPONSIVENESS TO A PHARMACEUTICAL THERAPY FOR OBESITY
    59.
    发明申请
    METHOD FOR PREDICTING RESPONSIVENESS TO A PHARMACEUTICAL THERAPY FOR OBESITY 有权
    预防药物治疗效果的方法

    公开(公告)号：US20100248375A1

    公开(公告)日：2010-09-30

    申请号：US12743029

    申请日：2008-12-18

    申请人： Jennifer K. Leohr

    发明人： Jennifer K. Leohr

    IPC分类号： G01N33/92

    CPC分类号： G01N33/92 ,  G01N2800/044 ,  G01N2800/52

    摘要： Methods for using TRL V6 as a biomarker for the modulation of triglyceride and/or lipoprotein metabolism in a mammal induced by a weight loss pharmaceutical agent. The biomarker may be used for determining if an individual patient will likely respond favorably to a given weight loss pharmaceutical agent.

    摘要翻译： 使用TRL V6作为调节由减肥药剂引起的哺乳动物甘油三酯和/或脂蛋白代谢的生物标志物的方法。 生物标志物可用于确定个体患者是否可能对给定的减肥药剂有利地反应。